Back to Search
PHILIP LANDIS, M.D.
M.D.
Internal Medicine Physician
NPI: 1629162649Individual
Specialties, Licenses & Credentials
Research & Publications (20)
DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme.
PMID 19678815·BJU Int·2010
8-other
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging.
PMID 18614274·Eur Urol·2008
4-observational
Change in prostate cancer grade over time in men followed expectantly for stage T1c disease.
PMID 18207195·J Urol·2008
8-other
Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent.
PMID 18085616·Prostate·2008
8-other
Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.
PMID 17991538·Urology·2007
8-other
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience.
PMID 17936806·J Urol·2007
8-other
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.
PMID 17077354·J Natl Cancer Inst·2006
4-observational
Metabolic factors associated with benign prostatic hyperplasia.
PMID 16608892·J Clin Endocrinol Metab·2006
8-other
Delayed versus immediate surgical intervention and prostate cancer outcome.
PMID 16507832·J Natl Cancer Inst·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 75 PRINGLE WAY STE 601
RENO, NV 89502 - Phone
- (775) 982-5000
Quick Facts
- NPI
- 1629162649
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile